Treatment of Peripheral Neuropathy

Introduction to Peripheral Neuropathy Management

The American Diabetes Association recommends initiating first-line pharmacologic therapy with pregabalin (300-600 mg/day), duloxetine (60 mg once daily), or gabapentin (900-3600 mg/day) for peripheral neuropathy, while optimizing glycemic control and ruling out treatable causes 1, 2

Before attributing neuropathy to diabetes, the American Diabetes Association suggests excluding alternative treatable causes such as vitamin B12 deficiency, hypothyroidism, alcohol toxicity, neurotoxic medications, and renal disease 1
Alcohol toxicity should be assessed through detailed history 1
Neurotoxic medications, including chemotherapy agents, amiodarone, and HIV medications, should be considered as potential causes 1
Renal disease should be evaluated via comprehensive metabolic panel 1

Pregabalin is effective at a dose range of 300-600 mg/day divided into 2-3 doses, with common side effects including dizziness, somnolence, peripheral edema, and weight gain 1, 2, 4
Duloxetine is initiated at 30 mg once daily for one week, then increased to 60 mg once daily, with a maximum dose of 120 mg/day if needed, and may cause small increases in HbA1c with long-term use 1, 2
Gabapentin is started at 100-300 mg daily in elderly patients, titrated slowly to 900-3600 mg/day in three divided doses, and is better tolerated than pregabalin in some patients with edema concerns 2, 5

The American Diabetes Association recommends targeting HbA1c of 6-7% to prevent neuropathy progression, though this will not reverse existing nerve damage 1, 2, 3
Near-normal glycemic control effectively prevents diabetic peripheral neuropathy development in type 1 diabetes, while in type 2 diabetes, glycemic optimization modestly slows progression but does not reverse neuronal loss 1, 2, 3
Optimizing blood pressure to <140/90 mmHg and managing dyslipidemia aggressively are crucial, as hypertension is an independent risk factor for diabetic peripheral neuropathy 2, 4

Quantify pain using numeric rating scale (0-10) at each visit and assess functional impact on sleep, mood, and daily activities, treating concurrent sleep and mood disorders as they worsen neuropathic pain outcomes 2
Perform comprehensive foot examination every 3-6 months for high-risk patients, including annual 10-g monofilament testing to identify loss of protective sensation, vibration perception testing, and temperature or pinprick sensation assessment 1, 2, 3, 4

Prescribe specialized therapeutic footwear for all high-risk patients with loss of protective sensation and callus formation, including extra-wide or extra-depth shoes for bony deformities and custom-molded shoes for severe deformities or Charcot foot 2
Schedule immediate callus debridement and regular appointments every 4-8 weeks to prevent ulcer development 2
Refer all patients with loss of protective sensation, structural abnormalities, or history of lower-extremity complications to podiatry for ongoing preventive care 2

Refer to neurology or pain specialist when pain remains inadequately controlled after trials of at least two first-line medications at therapeutic doses, or when clinical features are atypical, diagnosis remains unclear, or consideration of spinal cord stimulation is needed 1, 2